olverembatinib,ponatinib
otsuka,innovent biologics,takeda,incyte,ascentage pharmaceuticals
['cml', 'ponatinib', 'olverembatinib', 'ph+ all', 'leukemia']
congress #ash22|
elias jabbour, shares the us-based phase 1b study results of olverembatinib in pts with tki-refractory cml and ph+ all which showed efficacy and safety up to 50mg qod; strong efficacy seen in pts with cml who were resistant to ponatinib #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm